UBS Commercial Mortgage Trust 2017-C3 has announced its distribution report for the month ending October 19, 2026. This update is significant as it reflects the trust's ongoing performance in the competitive asset-backed securities market.
The trust is part of the asset-backed securities industry, which involves the securitization of various financial assets. The latest filing, dated November 2, 2026, reveals critical insights into the trust's operations and financial health.
Background
UBS Commercial Mortgage Trust 2017-C3, identified under the Central Index Key (CIK) number 0001713226, operates within the asset-backed securities sector (SIC: 6189). The trust has been active in filing various reports, including its recent 10-D and ABS-EE filings on November 2, 2026. The trust is incorporated in Delaware and has its business address at 1285 Avenue of the Americas, New York, NY.
What the Filing Says
According to the recent filing, a distribution was made to certificate holders on October 19, 2026. The report states, "The distribution report is attached as an Exhibit to this Form 10-D, please see Item 10(b), Exhibit 99.1 for the related information." This indicates that the trust is maintaining its distribution schedule, which is vital for investor confidence.
Impact
This update may affect various stakeholders, including investors holding certificates issued by the trust. The filing also mentions that during the distribution period, no assets were subject to repurchase demands for breaches of warranties, suggesting a stable operational environment. Key players in the industry, such as UBS AG, Société Générale, and KeyBank, are also noted as sponsors and mortgage loan sellers, indicating a competitive landscape.
What's Next
The filing does not specify what happens next for the trust or its investors. However, continued monitoring of performance metrics and future distributions will be crucial for stakeholders.
Read Next
JPMorgan Chase Financial Co. files for new structured notes
JPMorgan Chase Financial files preliminary pricing supplement
Wise Group plc announces significant share repurchase
AEON Biopharma Amends Warrant Terms, Lowers Exercise Price
JPMorgan Chase Financial Co. files for new equity notes
Rentokil Initial plc announces share buyback program







